Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Multiple Myeloma 20Lymphoma 17Neoplasm Metastasis 14Leukemia, Myeloid, Acute 12Pancreatic Neoplasms 9Breast Neoplasms 9Ovarian Neoplasms 8Melanoma 8Lung Neoplasms 8Colorectal Neoplasms 8Sarcoma 7Prostatic Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 7Glioma 7Fallopian Tube Neoplasms 7Cholangiocarcinoma 7Neuroblastoma 6Lymphoma, Non-Hodgkin 6Lymphoma, Follicular 6Endometrial Neoplasms 6Lymphoma, Large B-Cell, Diffuse 5Ependymoma 5Burkitt Lymphoma 5Wilms Tumor 4Urinary Bladder Neoplasms 4Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Rhabdomyosarcoma 4Rhabdoid Tumor 4Neuroectodermal Tumors, Primitive, Peripheral 4

Interventions

atezolizumab 1Tiragolumab 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Advanced Rare Malignant Solid Neoplasm × Biopsy × Clear all
NCT05715281 2025-11-25

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
12 enrolled
Other solid neoplasm

Advanced Rare Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡